First-line treatment of lung cancer! Baxter-American O-Y combination chemotherapy 3 clinical reached the main end

Opdivo-Yervoy, BMS's immunooncology portfolio, has suffered in untreated non-small cell lung cancer trials, but the program is likely to succeed after adding new membersOctober 22, BMS announced a key Phase 3 clinical trial that showed that Opdivo plus small doses of Yervoy simultaneously combined chemotherapy first-line treatment of advanced non-small cell lung cancer (NSCLC) reached the primary endpoint of total survival (OS) in a pre-specified mid-stage analysis;The study, called CheckMate-9LA, was an open, multicenter, randomized phase 3 clinical study that compared opdivo (360 mg Q3W) and Yervoy (1 mg / kg Q6W) first-line chemotherapy (whether or not there is A D-L1 and tissue monitoring) with simple chemotherapy (up to four cycles, followed by optional pemephochet maintenance therapy)Patients in the trial group received treatment for up to two years, or until the disease progressed or were not acceptable, and patients in the control group received up to four cycles of chemotherapy and optional metamcinance maintenance therapy (if conditions are met) until the disease progressed or toxicity occurredThe primary endpoint is OS, and the secondary endpoint includes no progression lifetime, total mitigation rate, and performance indicators based on biomarkersbut this time, bmS did not disclose the secondary endpoint of the experiment and any more results than the OS dataBMS said it would continue to complete a comprehensive review of The CheckMate-9LA data, present the results at the upcoming conference and share the results with regulatorsis well known as Opdivo, a PD-1 immunocheckpoint inhibitor, which was first launched worldwide in July 2014But its path to success has not been plain sailing, with strong growth and market competition from rival Keytruda on the one handMarket data for 2018 showed Opdivo's full-year sales of $7.57 billion, up 31.4 percent, followed by Keytruda with full-year sales of $7.171 billion, but up 88.3 percent, on the other hand, comes from the failure of its own research, and Opdivo's current clinical trials, which cover all stages of multiple types of cancer, have repeatedly suffered setbacksThe most recent was in July, when Opdivo combined chemotherapy showed no advantage over chemotherapy in the NSCLC first-line treatment phase 3 studyBut another part of the study showed that the Opdivo-Yervoy combination appeared to be more advantageous, reducing the risk of death by 21 percentThis result is significant in the Keytruda-led market competitionpositive results from the BMS may also bode well for AstraZeneca, which is currently awaiting data from similar trials to evaluate the use of the chemotherapy drugs Combined With Imfinzi and Tremelimab (For the Standard Yervoy)latest results have also given investors hope that the BMS portfolio will catch up with Mersadon's "weight class" in the market as soon as possible with the addition of chemotherapy drugsOf course, it's not that simpleAdding additional drugs to the drug mix would not only increase "some degree of treatment costs", but also increase toxicity levelsAs a result, some analysts have pointed out that the commercial value of CheckMate-9LA will depend on the balance between clinical benefits and toxicityThe benefit assessment of this risk will be possible only if complete results are providedFor now, the safety and tolerance of the BMS three-drug combination cocktail therapy is likely to be worse than the Keynote-189 trial in Mersadon, but whatever the final outcome, BMS shares opened up more than 5 per cent in the wake of the test resultsReference Source: UPDATED: Bristol-Myerss Opdivo Pitch for frontline front-line cancer with open label PhIII study